What is claimed is:

1. A pharmaceutical composition comprising crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A Form A), wherein at least about 85% of Compound A is in Form A.

2. The pharmaceutical composition of claim 1, wherein at least about 90% of Compound A is in Form A.

3. The pharmaceutical composition of claim 1, wherein at least about 95% of Compound A is in Form A.

4. The pharmaceutical composition of claim 1, wherein at least about 99% of Compound A is in Form A.

5. The pharmaceutical composition of claim 1, wherein at least about 99.5% of Compound A is in Form A.

6. The pharmaceutical composition of claim 1, wherein at least about 99.9% of Compound A is in Form A.

7. The pharmaceutical composition of claim 1, wherein at least about 99.99% of Compound A is in Form A.

8. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by a differential scanning calorimetry (DSC) curve that comprise an endotherm at about 223^{o}C.

9. The pharmaceutical composition of claim 8, wherein the DSC curve is substantially as shown in Figure 2.

10. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 8.5 °2θ ± 0.2 °2θ.

11. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 16.2 °2θ ± 0.2 °2θ.

12. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 27.4 °2θ ± 0.2 °2θ.

13. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising the following peaks: at 8.5, 16.2, and 27.4 °2θ ± 0.2 °2θ.

14. The pharmaceutical composition of claim 1, wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising the following peaks: at 8.5, 12.8, 16.2, 21.6, 22.9 and 27.4 °2θ ± 0.2 °2θ.

15. The pharmaceutical composition of claim 1, wherein the diffractogram is substantially as shown in Figure 1.

16. The pharmaceutical composition of claim 1, for use in therapy.

17. Use of a pharmaceutical composition of claim 1 in the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by hypoxia inducible factor (HIF).

18. The use of claim 17, wherein the condition mediated at least in part by HIF is tissue damage associated with ischemia or hypoxia.

19. The use of claim 18, wherein the ischemia is associated with an acute event selected from the group consisting of myocardial infarction, pulmonary embolism, intestinal infarction, chronic kidney failure, ischemic stroke, and renal ischemic-reperfusion injury.

20. The use of claim 18, wherein the ischemia is associated with a chronic event selected from the group consisting of cardiac cirrhosis, transient ischemic attack, macular degeneration, peripheral artery disease, and congestive heart failure.

21. Use of a pharmaceutical composition of claim 1 in the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by erythropoietin (EPO).

22. Use of a pharmaceutical composition of claim 1 in the manufacture of a medicament for treating, pretreating, or delaying onset or progression of anemia.

23. The use of claim 17, 21 or 22, wherein the compound used in the pharmaceutical composition is Compound A Form A.

24. The use of claim17, 21 or 22, wherein at least about 85% of the compound used in the pharmaceutical composition is Compound A Form A.

25. The use of claim17, 21 or 22, wherein at least about 90% of the compound used in the pharmaceutical composition is Compound A Form A.

26. The use of claim17, 21 or 22, wherein at least about 95% of the compound used in the pharmaceutical composition is Compound A Form A.

7. The use of claim17, 21 or 22, wherein at least about 99% of the compound used in the pharmaceutical composition is Compound A Form A.

28. The use of claim17, 21 or 22, wherein at least about 99.5% of the compound used in the pharmaceutical composition is Compound A Form A.

29. The use of claim17, 21 or 22, wherein at least about 99.9% of the compound used in the pharmaceutical composition is Compound A Form A.

30. The method of claim17, 21 or 22, wherein at least about 99.99% of the compound used in the pharmaceutical composition is Compound A Form A.